211 related articles for article (PubMed ID: 33753453)
1. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
Najjar YG; McCurry D; Lin H; Lin Y; Zang Y; Davar D; Karunamurthy A; Drabick JJ; Neves RI; Butterfield LH; Ernstoff MS; Puzanov I; Skitzki JJ; Bordeaux J; Summit IB; Bender JO; Kim JY; Chen B; Sarikonda G; Pahuja A; Tsau J; Alfonso Z; Laing C; Pingpank JF; Holtzman MP; Sander C; Rose A; Zarour HM; Kirkwood JM; Tarhini AA
Clin Cancer Res; 2021 Aug; 27(15):4195-4204. PubMed ID: 33753453
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.
Sharon CE; Tortorello GN; Ma KL; Huang AC; Xu X; Giles LR; McGettigan S; Kreider K; Schuchter LM; Mathew AJ; Amaravadi RK; Gimotty PA; Miura JT; Karakousis GC; Mitchell TC
Ann Oncol; 2023 Sep; 34(9):806-812. PubMed ID: 37414215
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
Tarhini AA; Cherian J; Moschos SJ; Tawbi HA; Shuai Y; Gooding WE; Sander C; Kirkwood JM
J Clin Oncol; 2012 Jan; 30(3):322-8. PubMed ID: 22184371
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.
Yokota K; Takenouchi T; Fujisawa Y; Fukushima S; Uchi H; Inozume T; Kiyohara Y; Uhara H; Nakagawa K; Furukawa H; Han S; Watanabe M; Noguchi K; Yamazaki N
J Dermatol; 2024 May; 51(5):632-642. PubMed ID: 38529706
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).
Yamazaki N; Takenouchi T; Fujimoto M; Ihn H; Uchi H; Inozume T; Kiyohara Y; Uhara H; Nakagawa K; Furukawa H; Wada H; Noguchi K; Shimamoto T; Yokota K
Cancer Chemother Pharmacol; 2017 Apr; 79(4):651-660. PubMed ID: 28283736
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Patel SP; Othus M; Chen Y; Wright GP; Yost KJ; Hyngstrom JR; Hu-Lieskovan S; Lao CD; Fecher LA; Truong TG; Eisenstein JL; Chandra S; Sosman JA; Kendra KL; Wu RC; Devoe CE; Deutsch GB; Hegde A; Khalil M; Mangla A; Reese AM; Ross MI; Poklepovic AS; Phan GQ; Onitilo AA; Yasar DG; Powers BC; Doolittle GC; In GK; Kokot N; Gibney GT; Atkins MB; Shaheen M; Warneke JA; Ikeguchi A; Najera JE; Chmielowski B; Crompton JG; Floyd JD; Hsueh E; Margolin KA; Chow WA; Grossmann KF; Dietrich E; Prieto VG; Lowe MC; Buchbinder EI; Kirkwood JM; Korde L; Moon J; Sharon E; Sondak VK; Ribas A
N Engl J Med; 2023 Mar; 388(9):813-823. PubMed ID: 36856617
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.
Unger JM; Darke A; Othus M; Truong TG; Khushalani N; Kendra K; Lewis KD; Faller B; Funchain P; Buchbinder EI; Tarhini AA; Kirkwood JM; Sharon E; Sondak V; Guild SR; Grossmann K; Ribas A; Patel SP
JAMA Oncol; 2023 Feb; 9(2):251-260. PubMed ID: 36416836
[TBL] [Abstract][Full Text] [Related]
9. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
Albertini MR; Yang RK; Ranheim EA; Hank JA; Zuleger CL; Weber S; Neuman H; Hartig G; Weigel T; Mahvi D; Henry MB; Quale R; McFarland T; Gan J; Carmichael L; Kim K; Loibner H; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2018 Oct; 67(10):1647-1658. PubMed ID: 30073390
[TBL] [Abstract][Full Text] [Related]
10. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.
Amber KT; Valdebran M; Lu Y; De Feraudy S; Linden KG
J Dtsch Dermatol Ges; 2018 Feb; 16(2):196-198. PubMed ID: 29389067
[No Abstract] [Full Text] [Related]
11. Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma.
Miura JT; Zager JS
Future Oncol; 2019 Nov; 15(32):3665-3674. PubMed ID: 31538818
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.
Lian B; Li Z; Wu N; Li M; Chen X; Zheng H; Gao M; Wang D; Sheng X; Tian H; Si L; Chi Z; Wang X; Lai Y; Sun T; Zhang Q; Kong Y; Long GV; Guo J; Cui C
Ann Oncol; 2024 Feb; 35(2):211-220. PubMed ID: 37956739
[TBL] [Abstract][Full Text] [Related]
13. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.
Silk AW; O'Day SJ; Kaufman HL; Bryan J; Norrell JT; Imbergamo C; Portal D; Zambrano-Acosta E; Palmeri M; Fein S; Wu C; Guerreiro L; Medina D; Bommareddy PK; Zloza A; Fox BA; Ballesteros-Merino C; Ren Y; Shafren D; Grose M; Vieth JA; Mehnert JM
Cancer Immunol Immunother; 2023 Jun; 72(6):1405-1415. PubMed ID: 36445410
[TBL] [Abstract][Full Text] [Related]
14. Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial.
Ellingsen EB; O'Day S; Mezheyeuski A; Gromadka A; Clancy T; Kristedja TS; Milhem M; Zakharia Y
Clin Cancer Res; 2023 Aug; 29(16):3026-3036. PubMed ID: 37378632
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial.
Olivier T; Prasad V
Transl Oncol; 2024 Apr; 45():101959. PubMed ID: 38621314
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy of locally/regionally advanced melanoma.
Khunger A; Buchwald ZS; Lowe M; Khan MK; Delman KA; Tarhini AA
Ther Adv Med Oncol; 2019; 11():1758835919866959. PubMed ID: 31391869
[TBL] [Abstract][Full Text] [Related]
17. Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma.
Błoński PJ; Czarnecka AM; Ostaszewski K; Szumera-Ciećkiewicz A; Rutkowski P
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540282
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant immunotherapy improves outlook in high-risk melanoma.
Nierengarten MB
Cancer; 2023 Jul; 129(13):1952. PubMed ID: 37300812
[No Abstract] [Full Text] [Related]
19. Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812].
Sharon CE; Tortorello GN; Ma KL; Huang AC; Xu X; Giles LR; McGettigan S; Kreider K; Schuchter LM; Mathew AJ; Amaravadi RK; Gimotty PA; Miura JT; Karakousis GC; Mitchell TC
Ann Oncol; 2024 Apr; ():. PubMed ID: 38614876
[No Abstract] [Full Text] [Related]
20. Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma.
Holder AM; Wargo JA; Ross MI
Ann Surg Oncol; 2023 Nov; 30(12):6953-6957. PubMed ID: 37597079
[No Abstract] [Full Text] [Related]
[Next] [New Search]
